Other languages PeptiDream Inc.

Equities

4587

JP3836750004

Delayed Japan Exchange Other stock markets 06:27:15 26/06/2024 am IST			5-day change	1st Jan Change
2,447 ^JPY	+3.45%		+11.09%	+64.75%

14/06	PeptiDream and Novartis Agreement Becomes Effective with 28.3 Billion Yen Upfront Payment	MT
04/06	National Cancer Center and PeptiDream Announces the First Dosing of Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

National Cancer Center and PeptiDream Announces the First Dosing of Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma	04/06
Peptidream Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024	14/05
Novartis stärkt Radioligand-Pipeline mit Übernahme	02/05
Bourse Zurich: les indices terminent en rouge à la veille de la Fed	30/04
Novartis étend sa collaboration avec le japonais Peptidream	30/04
Novartis baut Zusammenarbeit mit japanischer PeptiDream in Krebsforschung aus	30/04
Peptidream Announces Expansion of Peptide Discovery Collaboration with Novartis	30/04
PeptiDream Inc. Announces Expansion of Peptide Discovery Collaboration with Novartis Pharma AG	30/04
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024	14/02
PeptiDream Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/02
PeptiDream Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	09/11
Peptidream Announces Update on PDL1 Program Partnered with Bristol-Myers Squibb Company	26/23/26
PeptiDream Inc. Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide- Radioisotope Drug Conjugates	20/23/20
RayzeBio, Inc. has completed an IPO in the amount of $310.9968 million.	14/23/14
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	09/23/09
PeptiDream Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	09/23/09
Astellas Pharma Inc. and PeptiDream Inc. Enter into Research Collaboration and License Agreement to Discover Novel Targeted Protein Degraders	25/23/25
PeptiDream Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023	11/23/11
PeptiDream Inc. Announces Nomination of Second Peptide Radiopharmaceutical Therapeutic Development Candidate	22/23/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages PeptiDream Inc.

Equities

4587

JP3836750004

Other languages

Filters